CMS seeks comment on health agency readiness database

The Centers for Medicare & Medicaid Services plans to assess public health agencies' readiness for Meaningful Use reporting requirements and create a database to aid healthcare providers if the agencies are unprepared. The agency published a notice on the database in the May 16 Federal Register.

The reporting of information to public health agencies and registries goes from optional under Stage 1 to mandatory under Stage 2. CMS cited public feedback during the creation of the Stage 2 final rule that noted the burden providers would face to determine whether a public health agency can receive electronic data. That burden "could be nearly eliminated if we were to maintain a database on the readiness of public health agencies and registries." CMS "established that we would create such a database and it would serve as the definitive information source for determining public health agency and registry readiness to receive electronic data associated with the public health Meaningful Use objectives. The information will be made publicly available on the CMS website in order to provide a centralized repository of this information to eligible providers and eliminate there multiple individual inquiries to multiple public health agencies and registries."

CMS is accepting public comment on the proposed data collection until June 16.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.